We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

183 hedge funds and large institutions have $387M invested in Tvardi Therapeutics in 2022 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 48 increasing their positions, 71 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

223% more call options, than puts

Call options by funds: $4.35M | Put options by funds: $1.35M

13% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 23

5% more capital invested

Capital invested by funds: $368M → $387M (+$19.3M)

1% more funds holding

Funds holding: 181 → 183 (+2)

0.07% more ownership

Funds ownership: 1.57% → 1.65% (+0.07%)

32% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 71

Holders
183
Holders Change
+2
Holders Change %
+1.1%
% of All Funds
2.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
48
Reduced
71
Closed
23
Calls
$4.35M
Puts
$1.35M
Net Calls
+$3M
Net Calls Change
+$306K

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$5.7M
2
PA
Pinnacle Associates
New York
+$4.08M
3
KCM
Kingdon Capital Management
New York
+$3.42M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.97M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.41M

Top Sellers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
-$3.06M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.57M
3
Renaissance Technologies
Renaissance Technologies
New York
-$2.3M
4
C
Chescapmanager
Maryland
-$1.48M
5
CSS
Cubist Systematic Strategies
Connecticut
-$1.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
CA
176
Centerpoint Advisors
Massachusetts
$1K – – –
CFGS
177
Concourse Financial Group Securities
Alabama
$1K – – –
SIS
178
Sound Income Strategies
Florida
$1K – – –
FPS
179
Fieldpoint Private Securities
Connecticut
$1K +$1.23K +3 New
RWML
180
RAFFA WEALTH MANAGEMENT, LLC
District of Columbia
$936 – – –
Macquarie Group
181
Macquarie Group
Australia
$18 – – –
OQS
182
Occudo Quantitative Strategies
Florida
– -$778K -1,774 Closed
DTL
183
Dynamic Technology Lab
Singapore
– -$568K -1,295 Closed
CANY
184
Caxton Associates (New York)
New York
– -$268K -610 Closed
EGM
185
Engineers Gate Manager
New York
– -$258K -588 Closed
WG
186
Winton Group
United Kingdom
– -$247K -564 Closed
BAM
187
Blueshift Asset Management
New Jersey
– -$237K -541 Closed
ECM
188
Everence Capital Management
Indiana
– -$211K -481 Closed
Victory Capital Management
189
Victory Capital Management
Texas
– -$194K -442 Closed
Squarepoint
190
Squarepoint
New York
– -$176K -401 Closed
Rafferty Asset Management
191
Rafferty Asset Management
New York
– -$173K -394 Closed
AIM
192
Aigen Investment Management
New York
– -$155K -350 Closed
Man Group
193
Man Group
United Kingdom
– -$133K -303 Closed
AGM
194
Alpine Global Management
New York
– -$126K -287 Closed
RJA
195
Raymond James & Associates
Florida
– -$125K -285 Closed
CA
196
Cornerstone Advisory
Maryland
– -$16K -37 Closed
CG
197
Cutler Group
California
– -$15.2K -37 Closed
EVM
198
Eaton Vance Management
Massachusetts
– -$6K -13 Closed
HFS
199
Horizon Financial Services
North Carolina
– -$2.95K -7 Closed
TC
200
Truvestments Capital
Florida
– -$3K -7 Closed
5 6 7
8
9

TVRD Hedge Fund Activity: Q1 2022 in Review

183 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q1 2022, worth a combined $387M — up 5.3% from $368M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new TVRD positions and 23 closed out — a net gain of 3 holders — while 48 added to existing stakes and 71 trimmed.

The largest buyer was Farallon Capital Management, adding an estimated $5.7M. The largest seller was Soleus Capital Management, cutting an estimated $3.06M.

  • 183 institutional investors held Tvardi Therapeutics (TVRD) as of Q1 2022, up from 181 in Q4 2021.
  • Funds reported $387M of Tvardi Therapeutics stock for Q1 2022, up 5.3% quarter-over-quarter.
  • 26 funds opened new Tvardi Therapeutics positions in Q1 2022 and 23 closed out, a net change of +3 holders.
  • The largest Tvardi Therapeutics buyer in Q1 2022 was Farallon Capital Management, an estimated $5.7M added.
  • The largest Tvardi Therapeutics seller in Q1 2022 was Soleus Capital Management, an estimated $3.06M sold.

Based on aggregated 13F filings for Q1 2022.